Urinary Tract Infection
A urinary tract infection (UTI) is an infection that can occur in any part of the urinary tract, most commonly affecting the urethra or bladder, and is characterized by symptoms such as painful urination, frequent and urgent need to urinate, and suprapubic pain, with kidney infections also presenting fever and flank pain. Symptoms may be more subtle or non-specific in very young or elderly individuals.
Health Outcomes
- Absence of Serious Adverse Events
- Achieved Clinical Cure
- Achieved Complete Symptom Cessation
- Achieved Culture Negativity
- Adverse Safety Concern from Antimicrobial Resistance
- Alleviated Organ Injury from E. coli O78
- Altered Antibiotic Susceptibility
- Altered Lactobacilli Composition
- Complete Resolution of Symptoms
- Delayed Onset of Urinary Tract Infections
- Detected Antimicrobial Resistance Genes
- Detected Vaginal Colonization by Probiotic Strain
- Development of Pyuria
- Disrupted Bacterial Cell Membranes
- Disrupted Microbial Cell Membrane Integrity
- Enhanced Antibacterial Effect
- Enhanced Antimicrobial Peptide Levels
- Enhanced Antimicrobial Peptide Production
- Enhanced Innate Immune Function
- Enhanced Resistance to E. coli
- Genitourinary Adverse Events
- Improved Antagonistic Activity Against Undesirable Microorganisms
- Improved Antibiotic Resistance Outcomes
- Improved Antibiotic Sensitivity
- Improved Antibiotic Susceptibility
- Improved Biofilm Development
- Improved Clinical Cure Rate
- Improved Colonization Efficiency
- Improved Culture Negativity
- Improved Dysuria
- Improved Genitourinary Symptoms
- Improved Health Outcome Relative to Zinc Bacitracin
- Improved Hydration Status
- Improved Lactobacillus Counts
- Improved Microbial Identification
- Improved Microbial Safety
- Improved Phagocytic Activity
- Improved Resistance to Infections
- Improved Resistance to Pathogenic Infection
- Improved Survival Rate After Bacterial Challenge
- Improved Survival Rate Against Infection
- Improved Symptom Resolution
- Improved Symptoms of Acute Uncomplicated Cystitis
- Improved Urinary Frequency
- Improved Urinary Function
- Improved Urinary Tract Complication
- Improved Urogenital Tract Health
- Improved Urogenital Tract Symptoms
- Improved Vaginal Health Assessment Score
- Improved Water Intake
- Increased Abundance of Antibiotic Resistance Genes
- Increased Abundance of Lactobacillus Crispatus
- Increased Aerobic to Anaerobic Bacteria Ratio
- Increased Aggregation of Streptococcus agalactiae
- Increased Antagonistic Activity Against Undesirable Microorganisms
- Increased Antibacterial Activity
- Increased Antibiotic Susceptibility
- Increased Antimicrobial Resistance
- Increased Bacteremia Incidence
- Increased Bacterial Aggregation
- Increased Bacterial Survival
- Increased Body Temperature
- Increased Colonization by Administered Strain
- Increased Core Temperature
- Increased Cure Rate
- Increased Dispersal of Pathogenic Bacteria
- Increased Economic Burden Due to Higher Antibiotic Costs
- Increased Enterococcus Populations
- Increased Escherichia Coli Levels
- Increased Fever
- Increased Incidence of Pyuria
- Increased Infection
- Increased Lactobacilli Colonization
- Increased Lactobacilli Populations
- Increased Lactoferrin Level
- Increased Persistence of Probiotic Strains in Vaginal Tract
- Increased Rate of Recurrent Bacteremia
- Increased Risk of E. faecium Infection
- Increased Risk of Sepsis
- Increased Sepsis
- Increased Sepsis Incidence
- Increased Tetracycline Resistance
- Increased Total Bacterial Count
- Increased Urine pH
- Increased Vaginal Lactobacilli Presence
- Increased Viable Bacteria Count
- Increased White Blood Cell Count
- Induction of Antimicrobial Chemokines
- Inhibited ESBL-Positive Escherichia Coli Growth
- Inhibited Pathogenic Microbes
- Inhibition of Harmful Bacterial Growth
- No Reduction in Streptococcus agalactiae
- Non-Toxic Colonization
- Occurrence of Septic Shock
- Occurrence of Unrelated Haematuria
- Persistent Enterococcus Isolation
- Plasmid-Mediated Niche Adaptation in Lactobacillaceae
- Presence of Multidrug-Resistant Sepsis
- Presence of Pyuria
- Prevented Pathogen Adherence
- Protected Bladder Microbiome
- Protection Against Bacterial Vaginosis
- Recovered from Bacteremia without Sequelae
- Reduced Acute Cystitis Episode
- Reduced Adhesion of Escherichia coli
- Reduced Anaerobic Gram-Negative Bacterial Counts
- Reduced Antibiotic Sensitivity
- Reduced Antibiotic Usage
- Reduced Antibiotic Use Due to Infections
- Reduced Antibiotic Use Incidence
- Reduced Antibiotic and Antiviral Use
- Reduced Antibiotic-Resistant Gram-Negative Bacteria Acquisition
- Reduced Antimicrobial Use
- Reduced Bacteremia Incidence
- Reduced Bacterial Colonization
- Reduced Bacterial Load
- Reduced Bacteriuria
- Reduced Biofilm Formation
- Reduced Cefotaxime-Resistant Enterobacterales Abundance
- Reduced Coliform Bacteria Levels
- Reduced Coliform Counts
- Reduced Community-Acquired Infection Incidence
- Reduced Cystitis Episode
- Reduced Cystitis Incidence
- Reduced Days on Antibiotic Therapy
- Reduced Duration of Antibiotic Usage
- Reduced Duration of Infectious Diseases
- Reduced Duration of Nosocomial Infections
- Reduced Dysuria
- Reduced E. coli Concentration
- Reduced E. coli Levels
- Reduced E. coli Pathogenic Effects
- Reduced ESBL-Producing Escherichia Coli Colonization
- Reduced Escherichia Coli Levels
- Reduced Escherichia coli Attachment
- Reduced Escherichia coli Growth
- Reduced Fecal Enterococci Levels
- Reduced Genitourinary Discomfort
- Reduced Gram-Negative Bacteria Levels
- Reduced Harmful Bacteria Species
- Reduced Harmful Microorganisms
- Reduced Hospitalization Requirement
- Reduced Impact of Gram-negative Microorganisms
- Reduced Incidence of Bacterial Infections
- Reduced Incidence of Infections
- Reduced Infection Duration
- Reduced Infection Episode
- Reduced Infection Incidence
- Reduced Infection Rate
- Reduced Infection Recurrence
- Reduced Infection Risk
- Reduced Infectious Complication
- Reduced Infective Outcome
- Reduced Localized Infection
- Reduced Microbial Infection
- Reduced Nocturia
- Reduced Nocturnal Frequency
- Reduced Pathogen Counts in Organs
- Reduced Pathogen Incidence
- Reduced Pathogenic Bacteria Levels
- Reduced Pathogenic Bacteria Load
- Reduced Pathogenic Bacterial Activity
- Reduced Pathogenic Bacterial Growth
- Reduced Pathogenic Bacterial Invasion
- Reduced Pathogenic Bacterial Motility
- Reduced Pathogenic Bacterial Populations
- Reduced Pathogenic Bacterial Species Level
- Reduced Pathogenic Contamination
- Reduced Pseudomonas Levels
- Reduced Pyelonephritis Episode
- Reduced Recurrence of Urinary Tract Infections
- Reduced Recurrent UTI
- Reduced Risk of Antimicrobial Resistance
- Reduced Sepsis
- Reduced Streptococcus agalactiae Growth
- Reduced Suprapubic Pain
- Reduced Symptomatic Urinary Tract Infection Episode
- Reduced Transmission of Antibiotic-Resistant Genes
- Reduced Treatment Duration
- Reduced Urinary Dysfunction
- Reduced Urinary Symptom Burden
- Reduced Urinary Tract Infection
- Reduced Urinary Tract Infection Incidence
- Reduced Urinary Tract Infection Symptoms
- Reduced Urinary Tract Inflammation
- Reduced Urinary Urgency
- Reduced Urine Dipstick Markers of Urinary Tract Infection
- Reduced Urogenital Infections
- Reduced Urogenital Pathogen Activity
- Reduced Urogenital Pathogen Growth
- Reduced Uropathogenic Bacterial Adhesion
- Reduced Vaginal Colonization
- Reduced Vaginal Dysbiosis-Associated Infection Risk
- Reduced Vaginal Irritation
- Reduced Vaginal Soreness
- Restored Urogenital Tract Microbiome
- Safety of Lactobacillus crispatus Consumption
- Septicemia Incidence
- Stable Antibiotic Susceptibility Profiles
- Stable Enterobacterial Numbers
- Synergistic Antibiotic Effect
- Unchanged Inflammatory Response
- Vaginal Colonization by Lactobacillus Strains